Publications - Sorriso Pharmaceuticals

Publications

The Lancet Gastroenterology & Hepatology

Safety and pharmacokinetics of SOR102, an oral bispecific inhibitor of TNF and interleukin-23 in healthy participants and patients with ulcerative colitis: a first-in-human, double-blind, randomised, placebo-controlled, phase 1 trial

Oral Administration of SOR102 Delivers Anti-TNF/IL-23 Activity Directly to Colonic Tissue and Drives Clinical and Pharmacodynamic Responses in Ulcerative Colitis Patients

ECCO presentation

Phase 1b study of SOR102, a novel, orally delivered bispecific anti-TNF/anti-IL-23 domain antibody in patients with mild to severe ulcerative colitis

Phase 1b study of SOR102, a novel, orally delivered bispecific anti-TNF/anti-IL-23 domain antibody in patients with mild to severe ulcerative colitis

UEG presentation

First In Human Study Of SOR102, A Novel, Orally Delivered Bispecific Anti-TNF/Anti-IL-23 Domain Antibody In Clinical Development For The Treatment Of Inflammatory Bowel Disease

Novel orally delivered bispecific antibody for local GI activity: SOR102, an anti-TNFα/anti-IL-23 antibody in clinical development for treatment of Inflammatory Bowel Disease